deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT03828539

Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine (HER-MES)

Head-to-head Study of Erenumab Against topiRamate-a Double-blind, Double Dummy Migraine Study to Assess Tolerability and Efficacy in a patiEnt -Centered Setting

Sponsor: Novartis Pharmaceuticals

Conditions Migraine
Interventions Erenumab Erenumab matching placebo Topiramate Topiramate matching placebo
Updated 23 times since 2019 Last updated: Oct 7, 2021 Started: Feb 22, 2019 Primary completion: Jul 29, 2020 Completion: Jul 29, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03828539, this PHASE4 trial focuses on Migraine and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 23 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jul 2024 · 32 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

23 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Nov 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Sep 2021 — Nov 2021 [monthly]

    Completed PHASE4

▶ Show 18 earlier versions

  1. May 2021 — Sep 2021 [monthly]

    Completed PHASE4

  2. Jan 2021 — May 2021 [monthly]

    Completed PHASE4

  3. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE4

  4. Nov 2020 — Dec 2020 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  5. Sep 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE4

  6. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE4

  7. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE4

  8. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  9. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE4

  10. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE4

  11. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE4

  12. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE4

  13. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE4

  14. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE4

  15. Jun 2019 — Oct 2019 [monthly]

    Recruiting PHASE4

  16. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE4

  17. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE4

  18. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE4

    First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Alzenau in Unterfranken, Germany , Bad Homburg, Germany , Bad Honnef, Germany , Bad Saarow, Germany , Bayreuth, Germany , Bergen, Germany , Berlin, Germany , Bielefeld, Germany , Bochum, Germany and 53 more locations